202 related articles for article (PubMed ID: 20927316)
1. An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo.
Rabbani SA; Ateeq B; Arakelian A; Valentino ML; Shaw DE; Dauffenbach LM; Kerfoot CA; Mazar AP
Neoplasia; 2010 Oct; 12(10):778-88. PubMed ID: 20927316
[TBL] [Abstract][Full Text] [Related]
2. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis.
Rabbani SA; Valentino ML; Arakelian A; Ali S; Boschelli F
Mol Cancer Ther; 2010 May; 9(5):1147-57. PubMed ID: 20423991
[TBL] [Abstract][Full Text] [Related]
3. Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver.
Van Buren G; Gray MJ; Dallas NA; Xia L; Lim SJ; Fan F; Mazar AP; Ellis LM
Cancer; 2009 Jul; 115(14):3360-8. PubMed ID: 19484792
[TBL] [Abstract][Full Text] [Related]
4. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.
Kenny HA; Leonhardt P; Ladanyi A; Yamada SD; Montag A; Im HK; Jagadeeswaran S; Shaw DE; Mazar AP; Lengyel E
Clin Cancer Res; 2011 Feb; 17(3):459-71. PubMed ID: 21149615
[TBL] [Abstract][Full Text] [Related]
5. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo.
Khalili P; Arakelian A; Chen G; Plunkett ML; Beck I; Parry GC; Doñate F; Shaw DE; Mazar AP; Rabbani SA
Mol Cancer Ther; 2006 Sep; 5(9):2271-80. PubMed ID: 16985061
[TBL] [Abstract][Full Text] [Related]
6. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
7. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
8. Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.
Duriseti S; Goetz DH; Hostetter DR; LeBeau AM; Wei Y; Craik CS
J Biol Chem; 2010 Aug; 285(35):26878-26888. PubMed ID: 20501655
[TBL] [Abstract][Full Text] [Related]
9. Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.
Zhang J; Sud S; Mizutani K; Gyetko MR; Pienta KJ
Neoplasia; 2011 Jan; 13(1):23-30. PubMed ID: 21245937
[TBL] [Abstract][Full Text] [Related]
10. Suppression of uPAR retards radiation-induced invasion and migration mediated by integrin β1/FAK signaling in medulloblastoma.
Nalla AK; Asuthkar S; Bhoopathi P; Gujrati M; Dinh DH; Rao JS
PLoS One; 2010 Sep; 5(9):e13006. PubMed ID: 20886051
[TBL] [Abstract][Full Text] [Related]
11. Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3).
Senthilkumar K; Arunkumar R; Elumalai P; Sharmila G; Gunadharini DN; Banudevi S; Krishnamoorthy G; Benson CS; Arunakaran J
Cell Biochem Funct; 2011 Mar; 29(2):87-95. PubMed ID: 21308698
[TBL] [Abstract][Full Text] [Related]
12. Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells.
Nalla AK; Gorantla B; Gondi CS; Lakka SS; Rao JS
Cancer Gene Ther; 2010 Sep; 17(9):599-613. PubMed ID: 20448670
[TBL] [Abstract][Full Text] [Related]
13. Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer.
LeBeau AM; Duriseti S; Murphy ST; Pepin F; Hann B; Gray JW; VanBrocklin HF; Craik CS
Cancer Res; 2013 Apr; 73(7):2070-81. PubMed ID: 23400595
[TBL] [Abstract][Full Text] [Related]
14. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.
Mauro CD; Pesapane A; Formisano L; Rosa R; D'Amato V; Ciciola P; Servetto A; Marciano R; Orsini RC; Monteleone F; Zambrano N; Fontanini G; Servadio A; Pignataro G; Grumetto L; Lavecchia A; Bruzzese D; Iaccarino A; Troncone G; Veneziani BM; Montuori N; Placido S; Bianco R
Sci Rep; 2017 Aug; 7(1):9388. PubMed ID: 28839232
[TBL] [Abstract][Full Text] [Related]
15. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
[TBL] [Abstract][Full Text] [Related]
16. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth.
Kunigal S; Lakka SS; Gondi CS; Estes N; Rao JS
Int J Cancer; 2007 Nov; 121(10):2307-16. PubMed ID: 17657740
[TBL] [Abstract][Full Text] [Related]
17. Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM).
Xu X; Cai Y; Wei Y; Donate F; Juarez J; Parry G; Chen L; Meehan EJ; Ahn RW; Ugolkov A; Dubrovskyi O; O'Halloran TV; Huang M; Mazar AP
PLoS One; 2014; 9(1):e85349. PubMed ID: 24465541
[TBL] [Abstract][Full Text] [Related]
18. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
19. 3-Hydroxyflavone inhibits human osteosarcoma U2OS and 143B cells metastasis by affecting EMT and repressing u-PA/MMP-2 via FAK-Src to MEK/ERK and RhoA/MLC2 pathways and reduces 143B tumor growth in vivo.
Lu KH; Chen PN; Hsieh YH; Lin CY; Cheng FY; Chiu PC; Chu SC; Hsieh YS
Food Chem Toxicol; 2016 Nov; 97():177-186. PubMed ID: 27600294
[TBL] [Abstract][Full Text] [Related]
20. The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style.
Margheri F; Luciani C; Taddei ML; Giannoni E; Laurenzana A; Biagioni A; Chillà A; Chiarugi P; Fibbi G; Del Rosso M
Oncotarget; 2014 Mar; 5(6):1538-53. PubMed ID: 24681666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
